

Technology Licensing Opportunity


Non-Confidential Summary



IMMUNOLOGICAL TEST FOR RESTENOSIS ROI# 08-006

Opportunity:

Researchers at the University of Saskatchewan have developed an immunological test for predicting and diagnosing restenosis in patients who undergo percutaneous coronary interventions (PCI), such as angioplasty and stent implantation.



Background:

Advanced glycation endproducts (AGEs) are a class of molecules present in tissues and blood that act on the receptor for AGEs (RAGE). The interaction of AGEs and full-length RAGE results in increased expression of pro-inflammatory mediators and induction of oxidative stress. These substances are involved in the development of atherosclerosis, clot formation and plaque instability. The soluble form of RAGE, known as sRAGE, lacks a transmembrane domain and circulates in the blood. sRAGE acts as a decoy for RAGE ligands, competing with full-length RAGE. Therefore, sRAGE has protective role and prevents the development of atherosclerosis and restenosis.

Invention:

In a human clinical trial, the researchers demonstrated that serum sRAGE levels are a highly predictive index for the development of restenosis following angioplasty and stent implantation. This is valuable information for determining an appropriate treatment plan and follow-up in coronary artery disease.

In one embodiment of the invention, a serum sample is obtained from a patient with acute coronary syndrome undergoing PCI; 2) a first portion of the sample is contacted with an sRAGE antibody; 3) a second portion of the sample is contacted with an AGE antibody; 4) the complexes formed are measured to determine an amount of sRAGE and/or AGE; and 5) the likelihood for the development of restenosis is determined.

Industry Liaison Office
15 Innovation Boulevard, Suite 250
Saskatoon, SK, S7N 2X8
Tel: (306) 966-1465


Technology Licensing Opportunity

Non-Confidential Summary



IMMUNOLOGICAL TEST FOR RESTENOSIS ROI# 08-006

Researcher profile:



Kailash Prasad, M.D., Ph.D.
Professor, Dept. of Physiology

Research interests:
Oxyradicals in cardiovascular diseases and diabetes.
Flaxseed and its components in cardiovascular disease
& diabetes.

Patent Status:

International Patent Application no. WO2010139063

Publication:

McNair ED, Wells CR, Qureshi M, Basran R, Pearce C, Orvold J, Devilliers J, Prasad K. Soluble Receptors for Advanced Glycation End Products (sRAGE) as a Predictor of Restenosis Following Percutaneous Coronary Intervention. *Clin. Cardiol.* 33: 678-685 (2010).

Development Stage:

Clinical

For more information, please contact:

Neal Lemon, MBA, Ph.D.
306-966-7340
neal.lemon@usask.ca

Industry Liaison Office
15 Innovation Boulevard, Suite 250
Saskatoon, SK, S7N 2X8
Tel: (306) 966-1465